Keeler Thomas Management LLC Invests $911,000 in GlaxoSmithKline plc (GSK)

Keeler Thomas Management LLC purchased a new stake in GlaxoSmithKline plc (NYSE:GSK) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,700 shares of the pharmaceutical company’s stock, valued at approximately $911,000.

Several other institutional investors have also bought and sold shares of GSK. Hotchkis & Wiley Capital Management LLC boosted its stake in shares of GlaxoSmithKline by 7.3% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company’s stock valued at $341,727,000 after buying an additional 569,600 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in shares of GlaxoSmithKline by 504.4% in the third quarter. Point72 Asset Management L.P. now owns 604,419 shares of the pharmaceutical company’s stock valued at $24,539,000 after buying an additional 504,419 shares in the last quarter. Seatown Holdings Pte. Ltd. purchased a new stake in shares of GlaxoSmithKline in the third quarter valued at approximately $20,148,000. Clark Estates Inc. NY boosted its stake in shares of GlaxoSmithKline by 145.3% in the fourth quarter. Clark Estates Inc. NY now owns 650,000 shares of the pharmaceutical company’s stock valued at $23,056,000 after buying an additional 385,000 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its stake in shares of GlaxoSmithKline by 2.3% in the third quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock valued at $520,827,000 after buying an additional 293,866 shares in the last quarter. Hedge funds and other institutional investors own 9.52% of the company’s stock.

Shares of GlaxoSmithKline plc (NYSE:GSK) opened at $36.49 on Monday. The company has a current ratio of 0.60, a quick ratio of 0.39 and a debt-to-equity ratio of 4.09. The company has a market capitalization of $90,462.29, a price-to-earnings ratio of 46.19, a price-to-earnings-growth ratio of 2.33 and a beta of 0.98. GlaxoSmithKline plc has a 12-month low of $34.52 and a 12-month high of $44.53.

GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 EPS for the quarter, topping the Zacks’ consensus estimate of $0.69 by $0.03. The company had revenue of $10.14 billion for the quarter, compared to the consensus estimate of $9.89 billion. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. equities analysts predict that GlaxoSmithKline plc will post 2.82 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd will be given a $0.633 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 annualized dividend and a dividend yield of 6.94%. The ex-dividend date of this dividend is Thursday, February 22nd. GlaxoSmithKline’s dividend payout ratio is currently 258.23%.

GSK has been the topic of a number of analyst reports. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research note on Wednesday, October 18th. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Wednesday, October 18th. Bank of America downgraded GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th. TheStreet upgraded GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Finally, Investec downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating to the company’s stock. GlaxoSmithKline has a consensus rating of “Hold” and a consensus target price of $38.57.

ILLEGAL ACTIVITY WARNING: This story was originally published by Week Herald and is owned by of Week Herald. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://weekherald.com/2018/02/12/keeler-thomas-management-llc-invests-911000-in-glaxosmithkline-plc-gsk.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply